What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?

International Journal of Gynecological Cancer

Volumn 18, Issue SUPPL. 1, 2008, Pages 36-39

  Markman, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Cisplatin; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL;

ABDOMINAL DISCOMFORT; ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; HUMAN; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION; VOMITING;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 40749092113     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01103.x     Document Type: Article

References (27)

1. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996 335 : 1950 5.
2. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001 19 : 1001 7.
3. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006 354 : 34 43.
4. Elit L, Oliver TK, Covens A et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 2007 109 : 692 702.
5. McGuire WP, Hoskins WJ, Brady MF et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995 13 : 1589 99.
6. Gore M, Mainwaring P, A'Hern R et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998 16 : 2426 34.
7. Jakobsen A, Bertelsen K, Andersen JE et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 1997 15 : 193 8.
8. Conte PF, Bruzzone M, Carnino F et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996 14 : 351 6.
9. Dittrich C, Sevelda P, Salzer H et al. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur J Cancer 2003 39 : 1129 40.
10. Howell SB, Pfeifle CL, Wung WE et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982 97 : 845 51.
11. Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep 1983 67 : 235 8.
12. Lopez JA, Krikorian JG, Reich SD et al. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol 1985 20 : 1 9.
13. Pretorius RG, Hacker NF, Berek JS et al. Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 1983 67 : 1085 92.
14. Alberts DS, Green S, Hannigan EV et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992 10 : 706 17.
15. Swenerton K, Jeffrey J, Stuart G et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992 10 : 718 26.
16. Covens A, Carey M, Bryson P et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002 85 : 71 80.
17. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003 21 : 3194 200.
18. Degregorio MW, Lum BL, Holleran WM et al. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 1986 18 : 235 8.
19. Elferink F, van der Vijgh WJ, Klein I et al. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 1988 21 : 57 60.
20. Speyer JL, Beller U, Colombo N et al. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol 1990 8 : 1335 41.
21. Pfeiffer P, Bennedbaek O, Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol 1990 36 : 306 11.
22. Fujiwara K, Markman M, Morgan M, Coleman RL. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2005 97 : 10 5.
23. Los G, Verdegaal EM, Mutsaers PH, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991 28 : 159 65.
24. Markman M, Reichman B, Hakes T et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol 1993 50 : 100 4.
25. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000 92 : 699 708.
26. Connelly E, Markman M, Kennedy A et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 1996 62 : 166 8.
27. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004 96 : 1682 91.